Table 2.

Subgroup analysis of mTSS CFB at week 52 by baseline parameters and concomitant MTX dose (FAS, LINEAR)

Parameter at baseline	Subgroup	CZP+MTX		PBO+MTX
		n	mTSS CFB mean±SD	n	mTSS CFB mean±SD
Anti-CCP antibody (U/mL)	<100	51	−0.03±0.69	51	1.34±3.11
	100–<300	57	0.11±1.99	56	1.52±3.79
	≥300	50	1.05±4.21	50	1.91±7.01
RF (IU/mL)	<20	6	−0.26±0.45	11	2.20±5.14
	20–<60	33	0.06±1.09	29	0.82±3.07
	≥60	119	0.48±3.06	117	1.72±5.20
CRP (mg/dL)	≤0.5	75	0.13±0.74	69	0.39±2.12
	>0.5–≤1.0	22	0.00±0.52	27	1.85±3.23
	>1.0	61	0.78±4.25	61	2.82±6.97
MMP-3 (ng/mL)	<50	36	0.09±0.50	33	0.01±0.42
	50–<100	59	0.31±0.97	50	1.44±3.17
	≥100	63	0.57±4.17	74	2.38±6.47
HAQ-DI	≤0.5	43	0.27±1.61	43	0.52±2.71
	>0.5–≤1.0	44	0.10±0.98	41	1.60±4.09
	>1.0	71	0.58±3.76	73	2.21±6.04
DAS28 (ESR)	<3.2	5	0.10±0.22	3	0.00±0.00
	3.2–5.1	60	0.20±0.83	54	0.71±3.14
	>5.1	93	0.49±3.46	100	2.10±5.59
mTSS	≤0.5	55	0.20±0.64	56	0.42±0.99
	>0.5	103	0.45±3.32	101	2.23±5.93
Concomitant MTX—average dose (mg/week)	0–8	18	0.07±0.88	21	0.61±2.37
	8–≤12	64	0.38±4.01	59	1.40±2.98
	>12–16	76	0.42±1.27	77	1.99±6.31

CCP, cyclic citrullinated peptide; CFB, change from baseline; CRP, C reactive protein; CZP, certolizumab pegol; DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire Disability Index; LINEAR, linear extrapolation; MMP-3, matrix metalloproteinase-3; mTSS, modified Total Sharp Score; MTX, methotrexate; PBO, placebo; RF, rheumatoid factor.